<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2200">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530357</url>
  </required_header>
  <id_info>
    <org_study_id>QAZCOV-I/II-01/2020</org_study_id>
    <nct_id>NCT04530357</nct_id>
  </id_info>
  <brief_title>Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine</brief_title>
  <official_title>Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-IN®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute for Biological Safety Problems</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Institute for Biological Safety Problems</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, blind, placebo-controlled phase- i study and randomized, open phase phase-ii
      study of QAZCOVID-IN®- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years
      old and elder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of the Phase-I clinical study Evaluation of the safety,acceptability and
      immunogenicity of QazCovid-in®-COVID-19 inactivated vaccine when administeredtwice in healthy
      volunteers aged 18-50 years.

      Purpose of the Phase-II clinical study Evaluation of the safety and immunogenicity of
      QazCovid-in® - COVID-19 inactivated vaccine with single and dual use in healthy volunteers
      aged 18 and above.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 19, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events up to seven days after immunization</measure>
    <time_frame>Seven days after each immunization</time_frame>
    <description>Frequency of adverse reaction in the seven days following each immunization per age group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events up to 21 days after immunization</measure>
    <time_frame>21 days after each immunization</time_frame>
    <description>Frequency of adverse reaction in the 21 days following each immunization per age group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo</measure>
    <time_frame>at days 0, 21, 27, 42, 180</time_frame>
    <description>The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA greater than ≥ 4 times 21 days following the second vaccination and 180 days following the first vaccination, compared with a placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events during the study</measure>
    <time_frame>throughout the study, an average of 180 days</time_frame>
    <description>Incidence of serious adverse events during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune profile</measure>
    <time_frame>at days 0, 7, 21, 27, 42</time_frame>
    <description>Cell-mediated immune profile</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Vaccine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Phase 1 Adult-vaccine (A Sample, blind study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Adult-Placebo (A Sample, blind study)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Adult-Vaccine, twice vaccination (An Open study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Elderly-Vaccine, twice vaccination (An Open study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Adult-Vaccine, single vaccination (An Open study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Elderly-Vaccine, single vaccination (An Open study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QazCovid-in® - COVID-19 inactivated vaccine</intervention_name>
    <description>QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan</description>
    <arm_group_label>Phase 1 Adult-vaccine (A Sample, blind study)</arm_group_label>
    <arm_group_label>Phase 2 Adult-Vaccine, single vaccination (An Open study)</arm_group_label>
    <arm_group_label>Phase 2 Adult-Vaccine, twice vaccination (An Open study)</arm_group_label>
    <arm_group_label>Phase 2 Elderly-Vaccine, single vaccination (An Open study)</arm_group_label>
    <arm_group_label>Phase 2 Elderly-Vaccine, twice vaccination (An Open study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)</description>
    <arm_group_label>Phase 1 Adult-Placebo (A Sample, blind study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability of signed and dated informed consent of the volunteer to participate in
             the study.

          -  Healthy male and female volunteers aged 18-50 and 50 and above.

          -  Ability and voluntary desire to independently keep records in the Self-Observation
             Diary, as well as to carry out all the repeated visits provided for in the study for
             control medical observation.

          -  The voluntary desire of females to use methods of reliable contraception throughout
             the entire period of their participation in the study.

          -  Negative results for IgM and IgG antibodies to SARS-CoV-2.

          -  Absence of COVID-19 diagnosis in history.

          -  Absence in the last 14 days of close contact with persons suspected of being infected
             with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with
             laboratory.

          -  Negative test results for human immunodeficiency virus (HIV), hepatitis B and
             hepatitis C.

        Exclusion Criteria:

          -  Aggravated allergic history, drug intolerance, including hypersensitivity to any of
             the components of the study drug, as well as a history of serious adverse events
             during vaccine administration (such as allergic reactions, respiratory failure,
             angioedema, abdominal pain).

          -  Acute illness with fever (body temperature ≥37.1°C) at the time of
             screening/randomization.

          -  Chronic alcohol and/or drug use in history.

          -  Clinically significant deviations from normal values during laboratory and/or imaging
             at screening.

          -  Women with a positive urine pregnancy test.

          -  Simultaneous treatment with immunosuppressive drugs, including corticosteroids (2
             weeks) 4 weeks prior to study drug administration.

          -  Acute or chronic clinically significant lesions of the lungs, cardiovascular system,
             gastrointestinal tract, liver, blood system, skin, endocrine, neurological and
             psychiatric diseases or impaired renal function (asthma, diabetes, thyroid disease,
             arrhythmia, myocardial infarction, severe hypertension not controlled by drugs, etc.),
             identified based on medical history, physical examination or clinical laboratory tests
             that, according to the researcher, may affect the study result.

          -  Disruption of platelets or other blood clotting disorders, which may cause
             contraindications to intramuscular administration.

          -  Leukemia or neoplasm in history.

          -  Persons with autoimmune diseases.

          -  Volunteers who received antiviral drugs, immunoglobulin's or blood transfusions or any
             other investigational drug within 4 weeks prior to study drug administration;

          -  Volunteers who received anti-inflammatory drugs 2 days before study drug
             administration;

          -  Participation in any other clinical research within the last 3 months.

          -  Volunteers with a concern that they will not comply with the study requirements, or
             persons with severe physical or mental disabilities that may affect the completion of
             the study.

          -  Voluntary refusal to study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berik Khairullin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kunsulu Zakarya, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan</name>
      <address>
        <city>Gvardeyskiy</city>
        <state>Jambul</state>
        <zip>080409</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine, I/II phase, safety, immunogenicity, QazCovid-in®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

